{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100000000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"The maximum effective dose (MED) of CD45RA-depleted DLI, defined as the maximum value of doses that satisfy the proportion of patients with their memory T cell count measured at week 4 post-DLI more than 300/uL is more than 50% and the toxicity of grade 3-4 aGVHD is less than 20%. Dose selection used a protocol-specified algorithm.","groups":[{"description":"Patients who met eligibility criteria and received transplant during the dose-finding phase.","id":"OG000","title":"Dose Finding Transplant Participants"}],"paramType":"NUMBER","populationDescription":"Patients who met eligibility criteria and received transplant during the dose-finding phase.","reportingStatus":"POSTED","timeFrame":"4 weeks post-DLI (up to approximately 12 weeks post-transplant)","title":"Maximum Effective Dose for Prophylactic CD45RA-depleted DLI","type":"PRIMARY","unitOfMeasure":"cells/kg"}